Clinical Trial Update: Window of Opportunity Trial of Durvalumab (MEDI4736) or Durvalumab/Tremelimumab as Neoadjuvant Chemotherapy to Identify Immune Dynamics in Surgically Resectable Head and Neck Cancer Patients. [Phase 2]

View source ↗

Summary

Phase 2 window-of-opportunity trial evaluating Durvalumab alone or Durvalumab plus Tremelimumab as neoadjuvant therapy to study immune dynamics in surgically re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Durvalumab (durvalumab)
• Durvalumab/Tremelimumab (durvalumab + tremelimumab)

Snippet

Sponsor: Yonsei University | Conditions: Stage II-IVB Operable HNSCC Oral Cavity, Hypopharynx | Phase 2 | Status: UNKNOWN